We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- obesity/erectile dysfunction

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (425)1/17/2019 2:33:06 PM
From: scaram(o)uche   of 435
Thanks. Here is the phase I.....

>> ZGN-1061 is not readily distributed to the central nervous system and, therefore, may not be expected to result in comparable sleep-related AEs. <<

>> Four subjects (3 in the 0.6?mg ZGN-1061 group and 1 in the 1.8?mg ZGN-1061 group in the MAD phase) had D-dimer levels that exceeded the upper limit of normal (ULN) by >1.5-fold (0.81?mg/L FEU). None of these elevations was found to be indicative of VTE. These elevations occurred as a single isolated measurement, that is, occurred during the follow-up period, 28?days post-last dose (n?=?1), or coincided with known non-VTE related causes of D-dimer elevation (sampling from blocked catheter [n?=?1], tooth infection/root canal [n?=?1], multiple hematomas at venipuncture sites [n?=?1]). <<

Molecule clearly differentiates from belanorib, but it's a four week trial.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext